{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-008080","form_type":"8-K","ticker":"COLL","cik":"0001267565","company_name":"COLLEGIUM PHARMACEUTICAL, INC","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.224118+00:00","generated_at":"2026-06-15T20:48:40.526181+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Collegium reports record Q1 revenue $144.8M, adjusted EPS $1.32, reaffirms FY23 guide","bullets":["Record product revenue net of $144.8M, up 73% YoY from $83.8M.","Non-GAAP adjusted net income $51.7M with adjusted EPS $1.32 vs $0.71 YoY.","Adjusted EBITDA $87.6M, up 101% YoY from $43.5M.","Cash balance $269.5M; completed $241.5M convertible note offering due 2029.","Reaffirmed FY23 product revenue $565-580M and adjusted EBITDA $355-370M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-008080","json":"https://secwatch.observer/filing/0001558370-23-008080.json","markdown":"https://secwatch.observer/filing/0001558370-23-008080.md","text":"https://secwatch.observer/filing/0001558370-23-008080.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023008080/0001558370-23-008080-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023008080/coll-20230504x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:48:40.526181+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2063171073c9aa61dd1533ac802db291f01ede7a","claim":"COLLEGIUM PHARMACEUTICAL, INC reported Full Year 2023 results: revenue $565.0 to $580.0 million. Guidance reaffirmed.","evidence_excerpt":"The Company reaffirms its full-year 2023 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA: ​ Product Revenues, Net $565.0 to $580.0 million Adjusted Operating Expenses (Excluding Stock-Based Compensation) $135.0 to $145.0 million Adjusted EBITDA (Excluding Stock-Based Compensation) $355.0 to $370.0 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1267565/000155837023008080/0001558370-23-008080-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"Full Year 2023"},{"label":"Revenue","value":"$565.0 to $580.0 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}